PL2514764T3 - Cząsteczki przeciwciał, które wiążą il-17a i il-17f - Google Patents
Cząsteczki przeciwciał, które wiążą il-17a i il-17fInfo
- Publication number
- PL2514764T3 PL2514764T3 PL12175103T PL12175103T PL2514764T3 PL 2514764 T3 PL2514764 T3 PL 2514764T3 PL 12175103 T PL12175103 T PL 12175103T PL 12175103 T PL12175103 T PL 12175103T PL 2514764 T3 PL2514764 T3 PL 2514764T3
- Authority
- PL
- Poland
- Prior art keywords
- bind
- antibody molecules
- antibody
- molecules
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Dermatology (AREA)
- General Engineering & Computer Science (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0620729.4A GB0620729D0 (en) | 2006-10-18 | 2006-10-18 | Biological products |
EP07824232.8A EP2076539B1 (en) | 2006-10-18 | 2007-10-18 | Antibody molecules which bind il-17a and il-17f |
EP12175103.6A EP2514764B1 (en) | 2006-10-18 | 2007-10-18 | Antibody molecules which bind IL-17A and IL-17F |
PCT/GB2007/003983 WO2008047134A2 (en) | 2006-10-18 | 2007-10-18 | Antibody molecules which bind il-17a and il-17f |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2514764T3 true PL2514764T3 (pl) | 2019-08-30 |
Family
ID=37507977
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL07824232.8T PL2076539T3 (pl) | 2006-10-18 | 2007-10-18 | Cząsteczki przeciwciał, które wiążą il-17a i il - 17 f |
PL12175103T PL2514764T3 (pl) | 2006-10-18 | 2007-10-18 | Cząsteczki przeciwciał, które wiążą il-17a i il-17f |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL07824232.8T PL2076539T3 (pl) | 2006-10-18 | 2007-10-18 | Cząsteczki przeciwciał, które wiążą il-17a i il - 17 f |
Country Status (27)
Country | Link |
---|---|
US (6) | US8303953B2 (pl) |
EP (3) | EP2076539B1 (pl) |
JP (4) | JP2010506580A (pl) |
KR (1) | KR20090078355A (pl) |
CN (1) | CN101589061B (pl) |
AU (1) | AU2007311689B2 (pl) |
BR (1) | BRPI0717768B8 (pl) |
CA (1) | CA2666458C (pl) |
CO (1) | CO6180467A2 (pl) |
CY (2) | CY1117963T1 (pl) |
DK (2) | DK2076539T3 (pl) |
EA (1) | EA029953B1 (pl) |
ES (2) | ES2588596T3 (pl) |
GB (1) | GB0620729D0 (pl) |
HR (2) | HRP20161069T1 (pl) |
HU (2) | HUE029448T2 (pl) |
IL (1) | IL198061B (pl) |
LT (1) | LT2514764T (pl) |
MX (1) | MX2009003973A (pl) |
PL (2) | PL2076539T3 (pl) |
PT (2) | PT2076539T (pl) |
RS (1) | RS55031B1 (pl) |
SG (1) | SG175652A1 (pl) |
SI (2) | SI2514764T1 (pl) |
TR (1) | TR201907599T4 (pl) |
WO (1) | WO2008047134A2 (pl) |
ZA (1) | ZA200902460B (pl) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX341074B (es) | 2003-07-08 | 2016-08-05 | Genentech Inc | Polipeptidos heterologos il-17 a/f y usos terapeuticos de los mismos. |
WO2007106769A2 (en) | 2006-03-10 | 2007-09-20 | Zymogenetics, Inc. | Antibodies that bind both il-17a and il-17f and methods of using the same |
US7790163B2 (en) | 2006-03-10 | 2010-09-07 | Zymogenetics, Inc. | Antibodies that bind both IL-17A and IL-17F and methods of using the same |
US7910703B2 (en) | 2006-03-10 | 2011-03-22 | Zymogenetics, Inc. | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use |
GB0612928D0 (en) | 2006-06-29 | 2006-08-09 | Ucb Sa | Biological products |
GB0620729D0 (en) | 2006-10-18 | 2006-11-29 | Ucb Sa | Biological products |
KR101197378B1 (ko) | 2007-04-30 | 2012-11-05 | 인터디지탈 테크날러지 코포레이션 | Mimo 무선 통신 시스템에서의 에러 검출 및 검사의 피드백 시그널링 |
GB0807413D0 (en) | 2008-04-23 | 2008-05-28 | Ucb Pharma Sa | Biological products |
MX2010012090A (es) * | 2008-05-05 | 2011-04-11 | Novimmune Sa | Anticuerpos anti-il 17 a/il-17f de reactividad cruzada y metodos de uso de los mismos. |
US8790642B2 (en) | 2008-08-29 | 2014-07-29 | Genentech, Inc. | Cross-reactive and bispecific anti-IL-17A/F antibodies |
JP2012504953A (ja) * | 2008-10-07 | 2012-03-01 | ノビミューン エスアー | Il−17媒介性トランスフェクション法 |
EP3235509A1 (en) | 2009-03-05 | 2017-10-25 | AbbVie Inc. | Il-17 binding proteins |
CA2759848C (en) | 2009-05-05 | 2018-12-04 | Novimmune S.A. | Anti-il-17f antibodies and methods of use thereof |
SG185354A1 (en) | 2010-05-20 | 2012-12-28 | Ablynx Nv | Biological materials related to her3 |
GB201100282D0 (en) | 2011-01-07 | 2011-02-23 | Ucb Pharma Sa | Biological methods |
US10208349B2 (en) | 2011-01-07 | 2019-02-19 | Ucb Biopharma Sprl | Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy |
MA34907B1 (fr) | 2011-01-14 | 2014-02-01 | Ucb Pharma Sa | Molécules d'anticorps se liant à il-17a et il-17f |
PE20140880A1 (es) | 2011-02-08 | 2014-08-06 | Merck Patent Gmbh | Derivados de aminostatina para el tratamiento de artrosis |
WO2012125680A1 (en) * | 2011-03-16 | 2012-09-20 | Novartis Ag | Methods of treating vasculitis using an il-17 binding molecule |
WO2012138977A1 (en) * | 2011-04-06 | 2012-10-11 | Board Of Trustees Of The Leland Stanford Junior University | Structural based design of il-17 dominant negative mutants |
UA117218C2 (uk) * | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
CA3202536A1 (en) | 2012-05-10 | 2013-11-14 | Bioatla, Llc | Multi-specific monoclonal antibodies |
WO2013186236A1 (en) * | 2012-06-12 | 2013-12-19 | Orega Biotech | Antagonists of il-17 isoforms and their uses |
CN104231080B (zh) * | 2013-03-15 | 2019-07-02 | 中国医学科学院药物研究所 | 全人源抗人白介素17a单链抗体 |
GB201310544D0 (en) | 2013-06-13 | 2013-07-31 | Ucb Pharma Sa | Obtaining an improved therapeutic ligand |
RU2682046C1 (ru) * | 2013-11-18 | 2019-03-14 | Шанхай Хэнжуй Фармасьютикал Ко., Лтд. | Il-17a-связывающий агент и способы его применения |
TWI713453B (zh) | 2014-06-23 | 2020-12-21 | 美商健生生物科技公司 | 干擾素α及ω抗體拮抗劑 |
JP2018506275A (ja) * | 2015-01-28 | 2018-03-08 | ジェネンテック, インコーポレイテッド | 多発性硬化症の遺伝子発現マーカー及び治療 |
CN108251431B (zh) * | 2015-03-05 | 2020-12-08 | 北京百特美博生物科技有限公司 | 双载体系统及其用途 |
CN108350068A (zh) * | 2015-10-27 | 2018-07-31 | Ucb生物制药私人有限公司 | 使用抗-il-17a/f抗体的治疗方法 |
EA201990673A1 (ru) * | 2016-09-14 | 2019-08-30 | Бэйцзин Ханми Фарм. Ко., Лтд. | Антитела, специфически связывающиеся с il-17a, и их функциональные фрагменты |
GB201719447D0 (en) * | 2017-11-23 | 2018-01-10 | Ucb Biopharma Sprl | Pharmaceutical composition |
AU2021296436A1 (en) | 2020-06-23 | 2023-02-02 | Novartis Ag | Methods of treating Thyroid Eye Disease and Graves' Orbitopahy using Interleukin-17 (IL-17) antagonists |
CN112390890B (zh) * | 2020-11-06 | 2022-06-24 | 江苏荃信生物医药股份有限公司 | 一种定量检测血清中抗人白介素17单克隆抗体含量的酶联免疫分析方法 |
WO2024028436A1 (en) * | 2022-08-04 | 2024-02-08 | The University Of Birmingham | Novel interleukin-17a (il-17a)-derived peptide and neutralizing antibody (ab17-ipl-1) |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
DK336987D0 (da) | 1987-07-01 | 1987-07-01 | Novo Industri As | Immobiliseringsmetode |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
JP2538084B2 (ja) | 1988-06-28 | 1996-09-25 | イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー | 有害生物防除剤の錠剤配合物 |
JP3771253B2 (ja) | 1988-09-02 | 2006-04-26 | ダイアックス コープ. | 新規な結合タンパク質の生成と選択 |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
EP0542810A1 (en) | 1990-08-02 | 1993-05-26 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
CA2108147C (en) | 1991-04-10 | 2009-01-06 | Angray Kang | Heterodimeric receptor libraries using phagemids |
GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
GB9113120D0 (en) | 1991-06-18 | 1991-08-07 | Kodak Ltd | Photographic processing apparatus |
GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
US5885793A (en) | 1991-12-02 | 1999-03-23 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
EP0733070A1 (en) | 1993-12-08 | 1996-09-25 | Genzyme Corporation | Process for generating specific antibodies |
DK1231268T3 (da) | 1994-01-31 | 2005-11-21 | Univ Boston | Polyklonale antistofbiblioteker |
FR2716640B1 (fr) | 1994-02-28 | 1996-05-03 | Procedes Machines Speciales | Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion. |
US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
US6309636B1 (en) * | 1995-09-14 | 2001-10-30 | Cancer Research Institute Of Contra Costa | Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides |
JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
EP1053751A1 (en) | 1999-05-17 | 2000-11-22 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Compositions and methods for treating cell proliferation disorders |
US20070160576A1 (en) * | 2001-06-05 | 2007-07-12 | Genentech, Inc. | IL-17A/F heterologous polypeptides and therapeutic uses thereof |
US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
EP1545817B1 (en) | 2002-08-16 | 2016-11-02 | Allied Machine & Engineering Corp. | Drilling tool for producing port seals |
PT1570267E (pt) | 2002-12-03 | 2012-01-03 | Ucb Pharma Sa | Ensaio para a identificação de células produtoras de anticorpos |
GB0303337D0 (en) | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
CA2527020A1 (en) | 2003-07-01 | 2005-01-13 | Celltech R & D Limited | Modified antibody fab fragments |
MX341074B (es) | 2003-07-08 | 2016-08-05 | Genentech Inc | Polipeptidos heterologos il-17 a/f y usos terapeuticos de los mismos. |
EP1687026B1 (en) | 2003-11-21 | 2008-05-14 | UCB Pharma, S.A. | Method for the treatment of multiple sclerosis by inhibiting il-17 activity |
GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
WO2005123778A2 (en) * | 2004-06-10 | 2005-12-29 | Zymogenetics, Inc. | Soluble zcytor14, anti-zcytor14 antibodies and binding partners and methods of using in inflammation |
GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
GB0425569D0 (en) | 2004-11-19 | 2004-12-22 | Celltech R&D Ltd | Biological products |
EA200701211A1 (ru) * | 2004-12-31 | 2007-12-28 | Дженентек, Инк. | Полипептиды, которые связываются с br3, и их применение |
AR052289A1 (es) * | 2005-02-14 | 2007-03-07 | Wyeth Corp | Anticuerpos para interleucina-17f y otros antagonistas de la senalizacion de il-17f y sus usos |
EP3366702B1 (en) | 2005-12-13 | 2023-08-09 | Eli Lilly And Company | Anti-il-17 antibodies |
WO2007106769A2 (en) * | 2006-03-10 | 2007-09-20 | Zymogenetics, Inc. | Antibodies that bind both il-17a and il-17f and methods of using the same |
US7790163B2 (en) * | 2006-03-10 | 2010-09-07 | Zymogenetics, Inc. | Antibodies that bind both IL-17A and IL-17F and methods of using the same |
TW200815469A (en) | 2006-06-23 | 2008-04-01 | Astrazeneca Ab | Compounds |
GB0612928D0 (en) | 2006-06-29 | 2006-08-09 | Ucb Sa | Biological products |
CA2660463C (en) | 2006-08-11 | 2013-07-16 | Schering Corporation | Antibodies to il-17a |
GB0620729D0 (en) | 2006-10-18 | 2006-11-29 | Ucb Sa | Biological products |
GB0807413D0 (en) | 2008-04-23 | 2008-05-28 | Ucb Pharma Sa | Biological products |
MA34907B1 (fr) * | 2011-01-14 | 2014-02-01 | Ucb Pharma Sa | Molécules d'anticorps se liant à il-17a et il-17f |
-
2006
- 2006-10-18 GB GBGB0620729.4A patent/GB0620729D0/en active Pending
-
2007
- 2007-10-18 US US12/446,143 patent/US8303953B2/en active Active
- 2007-10-18 TR TR2019/07599T patent/TR201907599T4/tr unknown
- 2007-10-18 CA CA2666458A patent/CA2666458C/en active Active
- 2007-10-18 DK DK07824232.8T patent/DK2076539T3/da active
- 2007-10-18 PL PL07824232.8T patent/PL2076539T3/pl unknown
- 2007-10-18 HU HUE07824232A patent/HUE029448T2/en unknown
- 2007-10-18 SI SI200732113T patent/SI2514764T1/sl unknown
- 2007-10-18 SG SG2011076213A patent/SG175652A1/en unknown
- 2007-10-18 JP JP2009532894A patent/JP2010506580A/ja not_active Withdrawn
- 2007-10-18 ES ES07824232.8T patent/ES2588596T3/es active Active
- 2007-10-18 ZA ZA200902460A patent/ZA200902460B/xx unknown
- 2007-10-18 SI SI200731812A patent/SI2076539T1/sl unknown
- 2007-10-18 EP EP07824232.8A patent/EP2076539B1/en active Active
- 2007-10-18 WO PCT/GB2007/003983 patent/WO2008047134A2/en active Application Filing
- 2007-10-18 EP EP19160793.6A patent/EP3524623A1/en not_active Withdrawn
- 2007-10-18 KR KR1020097010040A patent/KR20090078355A/ko not_active Application Discontinuation
- 2007-10-18 HU HUE12175103A patent/HUE043667T2/hu unknown
- 2007-10-18 RS RS20160641A patent/RS55031B1/sr unknown
- 2007-10-18 EP EP12175103.6A patent/EP2514764B1/en active Active
- 2007-10-18 PT PT78242328T patent/PT2076539T/pt unknown
- 2007-10-18 BR BRPI0717768A patent/BRPI0717768B8/pt active IP Right Grant
- 2007-10-18 ES ES12175103T patent/ES2729064T3/es active Active
- 2007-10-18 LT LTEP12175103.6T patent/LT2514764T/lt unknown
- 2007-10-18 EA EA200900492A patent/EA029953B1/ru not_active IP Right Cessation
- 2007-10-18 AU AU2007311689A patent/AU2007311689B2/en active Active
- 2007-10-18 PT PT12175103T patent/PT2514764T/pt unknown
- 2007-10-18 CN CN200780043116.1A patent/CN101589061B/zh active Active
- 2007-10-18 DK DK12175103.6T patent/DK2514764T3/da active
- 2007-10-18 PL PL12175103T patent/PL2514764T3/pl unknown
- 2007-10-18 MX MX2009003973A patent/MX2009003973A/es active IP Right Grant
-
2009
- 2009-04-07 IL IL198061A patent/IL198061B/en active IP Right Grant
- 2009-05-14 CO CO09049372A patent/CO6180467A2/es not_active Application Discontinuation
-
2012
- 2012-10-01 US US13/632,702 patent/US8617847B2/en active Active
-
2013
- 2013-09-24 US US14/035,053 patent/US20140044732A1/en not_active Abandoned
- 2013-10-09 JP JP2013211558A patent/JP5856121B2/ja active Active
- 2013-12-16 US US14/107,314 patent/US20140186355A1/en not_active Abandoned
-
2015
- 2015-05-07 US US14/706,234 patent/US9890219B2/en active Active
- 2015-06-29 JP JP2015129677A patent/JP6329516B2/ja active Active
-
2016
- 2016-08-23 HR HRP20161069TT patent/HRP20161069T1/hr unknown
- 2016-09-06 CY CY20161100876T patent/CY1117963T1/el unknown
-
2017
- 2017-04-07 US US15/482,260 patent/US10308723B2/en active Active
- 2017-04-07 JP JP2017076759A patent/JP2017169569A/ja active Pending
-
2019
- 2019-05-21 HR HRP20190932TT patent/HRP20190932T1/hr unknown
- 2019-06-05 CY CY20191100595T patent/CY1121672T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200902460B (en) | Antibody molecules which bind IL-17A and IL-17F | |
IL193444A0 (en) | Antibodies that bind both il-17a and il-17f and methods of using the same | |
IL201281A0 (en) | Antibodies that bind both il - 17a and il-17f and methods of using the same | |
BRPI0715917A2 (pt) | Anticorpos para il-17a | |
HK1253391A1 (zh) | 與161p2f10b蛋白結合的抗體和相關分子 | |
IL242434B (en) | Antibody molecules with selectivity for 6-il of human origin | |
ZA200806492B (en) | Binding molecules | |
IL198592A0 (en) | Tes7 and antibodies that bind thereto | |
GB0621973D0 (en) | Binding molecules and uses thereof | |
IL194236A0 (en) | Antibody purification | |
DK3339445T3 (da) | Interleukin -13 bindende proteiner | |
DK2059535T3 (da) | Prlr-specifikt antistof og anvendelser deraf | |
HRP20130649T1 (hr) | Protutijela i povezane molekule koje se vežu za 24p4c12 proteine | |
ZA200901815B (en) | Binding molecules | |
PL2011869T3 (pl) | Nowe przeciwciało anty-CD98 | |
HK1118558A1 (en) | Reagents that bind ccx-ckr2 | |
ZA200709303B (en) | Antibodies and related molecules that bind to 161P2F210B proteins | |
GB0512225D0 (en) | Immunoglobulin molecules | |
GB0511881D0 (en) | Binding molecules | |
ZA201100565B (en) | Antibody purification |